Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
A recent study published in Annals of Internal Medicine reveals that smokers with type 2 diabetes who are treated with Novo Nordisk A/S' (NYSE:NVO) Ozempic (semaglutide) show fewer tobacco-related medical interactions and interventions aimed at smoking cessation compared to those taking other diabetes medications.
近期在《内科医学年鉴》上发表的一项研究显示，接受诺和诺德公司（纽交所：NVO）的Ozempic（塞麦肽）治疗的2型糖尿病患者，与服用其他糖尿病药物的患者相比，烟草相关的医疗互动和戒烟干预会更少。
In the year following the initiation of Ozempic treatment, patients previously diagnosed with tobacco use disorder were up to 32% less likely to discuss tobacco use with their healthcare providers.
在开始使用Ozempic治疗后的一年内，先前被诊断为吸烟障碍的患者与他们的医疗保健提供者讨论烟草使用的可能性会降低高达32％。
This reduction in discussions about tobacco use was observed even when compared to those taking other medications within the same class, known as GLP-1 receptor agonists.
即使与服用同类药物-GLP-1受体激动剂的其他患者相比较，这种关于烟草使用的讨论减少也会发生。
Also Read: UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages.
另外阅读：英国国家医疗服务体系因服务短缺而少开重量减轻药物Wegovy处方。
Additionally, Ozempic users were up to 68% less likely to receive prescriptions for smoking cessation medication and up to 21% less likely to receive smoking cessation counseling.
此外，使用Ozempic的用户减少了高达68％的戒烟药处方，并且降低了高达21％的接受戒烟咨询的可能性。
The study compared 222,942 new users of antidiabetes medications, including 5,967 of semaglutide.
该研究比较了222,942名新用药的抗糖尿病患者，其中包括5,967名服用塞麦肽。
Reuters notes that researchers highlighted the need for clinical trials to evaluate the potential of Ozempic's active ingredient, semaglutide, in smoking cessation.
路透社注意到，研究人员强调了需要进行临床试验来评估Ozempic的活性成分塞麦肽在戒烟方面的潜力。
The study, sponsored by the U.S. National Institutes of Health, suggests that semaglutide may reduce the desire to smoke by dampening the rewarding effects of nicotine in the brain.
由美国国立卫生研究院资助的这项研究建议，塞麦肽可能通过抑制大脑中尼古丁的奖励效应来降低吸烟的欲望。
The research added that semaglutide was associated with reduced smoking cessation medication prescriptions and counseling.
该研究还指出，塞麦肽与减少戒烟药和咨询的相关性有关。
Similar findings were observed in patients with and without a diagnosis of obesity. For most group comparisons, the differences occurred within 30 days of prescription initiation.
在肥胖和非肥胖患者中均观察到了类似的发现。对于大多数群体比较，差异发生在处方开始30天之内。
Despite the reduced tobacco disorder-related encounters, the study did not include data on whether patients stopped or decreased tobacco use after starting on the various drugs, the Reuters report added.
尽管减少了与烟草障碍有关的医疗互动，但研究没有包括关于患者在使用各种药物后是否停止或减少烟草使用的数据，据路透社报道。
While the observed reduction in medical interactions might suggest decreased tobacco use or relapses, researchers cautioned that it could also indicate a reduced willingness to seek help to quit smoking.
虽然观察到医疗互动减少可能暗示着烟草使用减少或复发，但研究人员警告称，这也可能表明减少了寻求戒烟帮助的意愿。
Price Action: NVO stock closed at $127.97 on Monday.
股价走势：NVO股票周一收盘价为127.97美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
- Oral Weight Loss Drugs Vs. Injections – Pills Are Promising Yet Challenging Frontier.
- 口服减肥药与注射减肥药—药片是一片充满希望但具有挑战性的前沿。
